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Abstract 
Introduction Given the low efficacy of smoking cessation methods, an experimental 
medicine model indicating smoking abstinence would be of great benefit to the development of 
new treatments. Hence the sensitivity of cognitive tasks and ambulatory craving measures to 
smoking abstinence were investigated. 
Methods Cognitive tasks and ambulatory ratings of craving were assessed for sensitivity 
to acute abstinence (experiment 1), and nicotine replacement therapy administration (NRT) 
(experiment 2). 
Results In experiment 1 go/no-go performance was improved (Mean Difference [MD] -
0.99, 95% CI: -1.90 to -0.08) and craving was lower (Regression Coefficient [RC] -33.39, 95% 
CI: -39.96 to -26.82) in satiated compared with abstinent smokers. There was no clear evidence 
that N-back (MD 0.64, 95% CI: -0.42 to 2.51), delay discounting (MD 0.01, 95% CI: 0.001 to 
0.005) or dot probe performance (MD 0.61, 95% CI: -0.87 to 1.54) were sensitive to acute 
abstinence. In experiment 2 go/no-go performance was improved (MD 1.12, 95% CI: 0.16 to 
2.08) and craving was lower (RC -18.59, 95% CI: -24.63 to -12.55) smokers abstinent overnight 
receiving NRT compared with placebo. There was no clear evidence that N-back (MD -0.25, 
95% CI: -1.45 to 0.94), delay discounting (MD 0.01, 95% CI: -0.002 to 0.004) or dot probe 
performance (MD -0.49, 95% CI: -1.61 to -0.64) were sensitive to NRT. 
Conclusions Findings from two experiments converge to suggest that abstinence in 
smokers reliably increases ambulatory craving assessments and, to a lesser extent, decreases 
go/no-go task performance. These findings can be utilized in the development of an experimental 
medicine model to test novel treatments for smoking cessation. 
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The development and validation of a human screening model of tobacco abstinence 
 
1. Introduction 
Most smokers are aware of the negative health consequences of smoking, but many are 
unable to quit even when using the best treatments currently available (Cahill et al., 2013). 
Although the need for novel treatments is clear, their development is expensive and time-
consuming. Experimental medicine models allow for the assessment of efficacy of novel 
compounds in healthy volunteers in a cost- and time-effective way (Lerman et al., 2007).  
Cognitive tasks might be able to inform about specific performance deficits during 
abstinence and could furthermore act as a precise objective measure of changes to the abstinence 
state. Moreover, there is a wealth of literature on smoking abstinence and cognitive impairment 
(Munafo et al., 2003, Myers et al., 2008, Ashare and Hawk, 2012, Leventhal et al., 2010, Park et 
al., 2000, Field et al., 2004). We previously reviewed the literature on the effect of acute 
abstinence on cognitive tasks (“acute abstinence studies”) and whether cognitive tasks can 
predict cessation attempt outcomes (“cessation studies”) (Grabski et al., 2016).  The design of 
cessation studies was too heterogeneous to permit meta‐analysis, hampering definite conclusions 
about the predictiveness of cognitive tasks on cessation outcomes.  In acute abstinence studies 
extensive variation in the tasks, methods and quality of study design were found as well, yet 
seven tasks were common enough in order to be meta-analysed. Meta-analyses revealed the 
following tasks to be sensitive to acute abstinence: delay discounting, response inhibition, 
recognition memory and mental arithmetic tasks, whereas several attentional bias measures 
based on manual reaction times were not (Grabski et al., 2016).  
 
Furthermore, cigarette craving might be a promising treatment target as it predicts (and 
may cause) relapse (Killen and Fortmann, 1997, Piper et al., 2011). However, several issues 
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need consideration when assessing cigarette craving as an indicator of abstinence. First, it is not 
well captured by the assessment of one single time point (Adams and Munafo, 2013); second, 
retrospective assessments are prone to memory bias (Shiffman, 2009); third, the ability of 
craving to predict relapse is influenced by the abstinence state of the smoker (Gass et al., 2014); 
and, fourth, the evidence is mixed regarding the sensitivity of craving to approved smoking 
cessation medications, such as nicotine replacement therapy (NRT), in short-term laboratory 
procedures (Teneggi et al., 2002). Some of these pitfalls can be avoided by the employment of 
ecological momentary assessment (EMA) methods, where participants are equipped with a 
portable device that collects information in their natural environment (Shiffman and Stone, 1998, 
Stone and Shiffman, 1994), as this would allow for the repeated, real-time assessment of craving 
(Shiffman et al., 2002, Shiffman and Waters, 2004). However, the risk of self-report bias 
remains. We therefore propose a screening model for tobacco abstinence including both, 
ambulatory measures of craving combined with cognitive performance measures, acting as a 
precise objective validation of the self-report measures 
The identification of objective measures of smoking status in combination with 
ambulatory craving assessments could be used to develop a time efficient screening model for 
novel smoking cessation treatments and could furthermore inform research efforts to use 
enhancement of cognitive performance as a treatment intervention (Sofuoglu et al., 2013, Ashare 
et al., 2014). 
Informed by our previous meta-analysis we set up a test battery including the following 
tasks: a delay discounting task (assessing impulsive decision making), a response inhibition task 
(assessing impulsive action), an N-back task (assessing working memory), an eye-tracking dot-
probe task (assessing attentional bias), an additionally EMA measures of craving severity. As we 
were previously not able to synthesise evidence on cessation studies we decided to focus on 
overnight abstinence only (Grabski et al., 2016). 
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In experiment 1, we manipulated acute withdrawal, and hypothesized that smokers would 
display worse working memory performance, impaired response inhibition, greater delay 
discounting and greater attentional bias towards smoking related cues over neutral cues in acute 
abstinence as compared to smoking satiety. In experiment 2, we compared abstinent smokers 
receiving active nicotine replacement therapy (NRT)—a treatment known to effectively reduce 
withdrawal symptoms and craving—in one session and placebo NRT in the other. We 
hypothesised that measures sensitive to acute abstinence in experiment 1 would be normalised in 
the active condition compared to placebo. 
 
2. Experiment 1 
2.1.  Methods 
2.1.1. Participants 
Participants were recruited from the general population. Participants were required to be 
between 18-60 years of age, have normal visual acuity, smoke a minimum of 5 cigarettes a day, 
smoke for at least 6 months and smoke within the first hour of waking. Exclusion criteria were 
currently trying to give up smoking, pregnancy, currently breast feeding or trying to conceive, the 
use of psychoactive medication, and a response of ‘no’ to the following statement: “I have no 
current or previous substance or alcohol misuse or dependence (other than nicotine and cannabis)”. 
Approval was granted by the Faculty of Science Research Ethics Committee at the University of 
Bristol. 
2.1.2. Materials 
Participants completed four tasks – a go/no-go task (assessing impulsive action through 
manual reaction times) (Hindocha et al., 2018) a delay discounting task (assessing impulsive 
decision making through decisions on hypothetical monetary rewards delay) (Hindocha et al., 
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2018), an N-back task (assessing working memory of letters), a dot probe task (assessing 
attentional bias through eye-movements) (Field et al., 2004) and an EMA procedure to assess 
cigarette craving  (Schüz et al., 2013) (for a detailed description of the tasks see Supplementary 
Material 1). 
2.1.3. Procedure 
Participants attended two test sessions, approximately one week apart. For one session 
participants were asked to abstain from smoking from midnight before the test day and 
throughout the day, while for the other session they were asked to smoke as they usually would. 
In this way participants in the abstinent condition would be abstinent for a minimum of 8 hours 
at the start of the laboratory session. The laboratory session lasted approximately two hours and 
was scheduled to begin in the morning between 8 – 11 am. The order of the two sessions was 
counterbalanced across participants. In the abstinent condition, abstinence from smoking was 
confirmed with a breath carbon monoxide (CO) sample reading of ≤10 ppm at the start of the 
laboratory session and at the end of the test day. If a participant arrived to the abstinent session 
with a higher CO than the cut-off point the session was cancelled and re-arranged, if possible. In 
the satiated condition participants were asked to smoke a cigarette 20 minutes before the start of 
the laboratory session, in order to standardize baseline nicotine levels.  
Following these procedures, readiness to quit (Contemplation Ladder) (Biener and 
Abrams, 1991), dependence (Fagerström Test of Cigarette Dependence, FTCD) (Heatherton et 
al., 1991) and craving (Questionnaire of Smoking Urges-Brief, QSU-Brief) (Cox et al., 2001) 
were assessed, after which participants completed the test battery, with the tasks randomized 
across and constant within participants. After the completion of two tasks participants were 
asked to take a short break. In the satiated condition participants were instructed to smoke a 
cigarette outside during the break, in order to prevent withdrawal. After the completion of the 
remaining test battery participants were provided with a mobile telephone device, which had 
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custom software running the EMA programme. They were instructed on how to use the device 
and to bring it back in the late afternoon (4-6 hours later). Participants in the abstinent condition 
were reminded to abstain from smoking until that time. On return to the laboratory participants 
were asked to provide another carbon monoxide reading and craving was assessed once more.  
 
2.1.4. Statistical Analysis 
Seventy participants were required to achieve 80% power and an alpha-level of 0.05 in 
order to detect the smallest effect size for the tasks included (d = 0.34 for the delay discounting 
task) as indicated by a meta-analysis of cognitive tasks sensitive to abstinence (Grabski et al., 
2016). 
For the go/no-go data, commission errors, omission errors and reaction times in the 
abstinent and satiated condition were analysed using dependent-samples t-tests. It was 
hypothesized that commission errors (i.e., false positives) would increase under acute 
abstinence, as previously reported (Grabski et al., 2016). 
For the N-back data, commission errors, omission errors and reaction times in the 
abstinent and satiated condition were analysed, using dependent-samples t-tests. It was 
hypothesised that omission errors (i.e., false negatives) would increase under acute abstinence 
(Grabski et al., 2016). 
For the delay discounting task data, the logged discounting parameter k (Odum, 2011) 
was derived from the indifference points from abstinent and satiated smokers and analyzed using 
a dependent-samples t-test. It was hypothesised that discounting would increase under acute 
abstinence (Grabski et al., 2016). 
For the dot probe task data, only critical trials were analyzed for both dwell time and bias 
scores of first saccades. First saccades were analyzed only if the saccade originated from the 
fixation cross in the center of the screen, this was the case for 88% of all saccades averaged 
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across abstinent and satiated sessions. Overall dwell time as well as bias scores of first saccades 
were each analyzed using a 2 × 2 repeated measures ANOVA. Picture type (smoking, neutral) 
and abstinence (abstinent, satiated) were included as a within-subject factors for the analyses of 
both. It was hypothesised that abstinent smokers would spend more time looking at smoking 
pictures over neutral pictures than satiated smokers (Field et al., 2004). 
For the EMA data, differences in craving measures between the abstinent and satiated 
state in the remote assessment component were analyzed using Generalized Estimating 
Equations (GEE). GEE are designed to account for the auto-correlation of data in repeated-
measures designs (Zeger et al., 1988).  
All analyses were conducted using R statistical software (Foundation for Statistical 
Computing, Vienna, Austria). The study protocol was pre-registered at the Open Science 
Framework (https://osf.io/5qgys/). The data that form the basis of the results presented here are 
available here: http://data.bris.ac.uk/data, doi XXXX. 
 
2.2. Results 
2.2.1. Characteristics of Participants 
We recruited 70 participants (29 female, 41%), with an average age of 21.8 years (SD 
5.0). The average FTCD score was 4.4 (SD 1.7) (Heatherton et al., 1991), participants reported 
they smoked 11 (SD 3.8) cigarettes per day and had a Contemplation Ladder score of 4.0 (SD 
0.9) . Due to technical error test battery results of one participant were lost as well as the results 
of two participants for the N-back task and the delay discounting task. Similarly, we were only 
able to obtain dot probe eye-tracking data for 60 participants. The EMA assessments from five 
participants were missing for at least one of the two sessions and therefore excluded. 
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The final analysis of the sample therefore comprised 69 participants for the go/no-go 
task, 67 participants for the N-back and the delay discounting tasks, 60 participants for the dot 
probe task and 65 for the EMA assessment.  
CO sample readings were markedly lower in the abstinence than in the satiated condition, 
confirming that participants adhered to the abstinence protocol (t[69] = 4.6, p<0.001). The QSU-
Brief results show that participants experienced higher cravings during the abstinent than during 
the satiated condition. (t[69] = 4.8, p<0.001) (see Table 1).  
 
2.2.2. Go/no-go task 
There was evidence for higher commission error rates in the abstinent condition than in 
the satiated condition (t[68] = -2.16, p = 0.034) (see Table 2). Ad-hoc analysis revealed that 
there were no session – order effects for go/no-go task performance or ambulatory craving 
assessments. Go/no-go commission error rates and ambulatory measures of craving were not 
associated (RC = 0.002, p = 0.628), nor were go/no-go commission error rate and a craving x 
condition interaction (RC = <0.001, p = 0.918). 
 
2.2.3. N-back task. 
There was no clear evidence for a difference omission errors in the abstinent and satiated 
condition (t[66] = 1.42, p = 0.16) (see Table 2). 
 
2.2.4. Delay discounting task. 
There was no clear evidence of a difference between the logged values of the discounting 
parameter k in the abstinent and satiated conditions (t[66] = 1.24, p = 0.25) (see Table 2). 
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2.2.5. Dot probe task 
There was evidence of a main effect of dwell time on picture type (F[1, 59] = 53.87, p < 
0.0001), with more time spent looking at smoking over neutral pictures, but no clear evidence of 
a main effect of session (F[1, 59] = 0.01, p = 0.91), or of a picture × session interaction effect 
(F[1,59] = 0.30, p = 0.58). The analysis of first saccade towards the stimuli revealed a main 
effect of dwell time on picture type (F[1, 59] = 55.45, p<0.0001), but no evidence of a main 
effect of session (F[1, 59] = 0.32, p = 0.57), or of a picture × session interaction effect (F[1,59] = 
0.87, p = 0.35) (for mean differences see Table 2). 
 
2.2.6. Ecological momentary assessment 
Each participant received about 4.4 prompts (SD 1.35) per session and the duration 
between first and last prompt was 3.85 hours (SD 1.49) on average. The number of prompts 
received did not differ greatly between conditions (N[abstinent] = 298, N[satiated] = 305). 
Compliance was good with 92% of prompts answered, more prompts were missed in the satiated 
condition (N[abstinent] = 19, N[satiated] = 33). The mean craving score in the abstinent 
condition was 75.0 (SD 24.1) and in the satiated condition 41.3 (SD 28.6). The mean craving 
score for the very first prompt received was 74.93 (SD) in the abstinent condition and 44.70 (SD 
28.68) in the satiated condition. 
Smoking condition (abstinent versus satiated) was found to be highly predictive of 
craving levels (RC = -33.39, p<0.0001) when included as the only predictor of craving in the 
model. Time (minutes since midnight) was not found to predict craving when added to the model 
(RC = 0.02; p = 0.160). There was weak evidence for an abstinence × time interaction term (RC 
= -0.04; p = 0.061). The decrease of the effect of condition on craving in model 3 is likely due to 
multicollinearity, which inflated the standard error (see Table 3). 
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2.3.  Discussion Experiment 1 
Response inhibition performance on the go/no-go task and ambulatory craving levels 
were sensitive to acute abstinence in regular smokers, whereas N-back, delay discounting and 
dot probe eye-tracking performance were not. In experiment 2, we investigated whether these 
results would be echoed when comparing abstinent smokers randomised to receive active NRT 
versus placebo.  
 
3. Experiment 2 
3.1.  Methods 
Methods were identical to those in experiment 1 unless indicated otherwise. Approval 
was granted by the Faculty of Science Research Ethics Committee at the University of 
Bristol. 
 
3.1.1.  Procedure 
Participants attended two sessions about 1 week apart. On both sessions participants had 
to abstain from smoking from midnight before the test session until the end of the testing day, 
requiring to abstain for a minimum of 8 hours before the start of the session. In one session 
participants received an NRT patch (14 mg) and nasal spray (10 mg/ml), on the other session a 
matching placebo patch and spray (Rusan Pharma, Ltd.). The order of the two sessions was 
counterbalanced across participants, and participants were blind to treatment condition. The two 
sessions were identical in procedure: They were scheduled to begin in the morning between 8 – 
11 am. The patches were applied to the participants’ arm at the beginning of the test session, 
then they were asked to use the nasal spray once. A 30-minute break was scheduled, to ensure 
sufficiently high blood levels of nicotine before the laboratory assessments. The laboratory 
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assessment lasted about 2 hours. After the completion of the laboratory assessments participants 
were instructed to use the spray throughout the day whenever they experienced cravings. On 
return to the test-site the patch was removed, the nicotine spray collected and times of use of the 
spray recorded. 
 
3.1.2. Statistical Analysis  
Analysis procedures were identical to those described for Experiment 1. The study 
protocol was pre-registered at the Open Science Framework (https://osf.io/apsjx/). The data that 
form the basis of the results presented here http://data.bris.ac.uk/data, doi XXXX. 
 
3.2. Results 
3.2.1. Characteristics of participants 
We recruited 70 participants (38 female, 54%), with an average age of 22.5 years (SD 
6.3). The average FTCD score (Heatherton et al., 1991) was 3.4 (SD 1.5), participants reported 
that they smoked 9.3 cigarettes per day (SD 3.5) and had a Contemplation Ladder score (Cox et 
al., 2001) of 4.4 (SD 1.0) (see Table 1).Participants in the placebo condition reported using the 
nasal spray 1.41 times on average and in the active condition 0.78 times over the course of the 
afternoon (Table 1). 
Four participants dropped out of the study because they were unable to tolerate the 
treatment. These participants were replaced. On all occasions this was during the active NRT 
condition, and all four participants named nausea as the main reason for deciding to discontinue. 
Their daily intake was on average 8.7 cigarettes (SD 1.8), and thus only slightly lower than the 
average of the overall study sample.  
Human Screening Model of Tobacco Abstinence 
 14 
The results of one participant for the delay discounting task, three participants for the 
go/no-go and the N-back tasks, and seven participants for the eye-tracking task were missing due 
to technical error. For the EMA assessment data from eight participants were missing for at least 
one of the two sessions and therefore excluded. The final sample for analysis therefore 
comprised 69 participants for the delay discounting task, 67 participants for the N-back and the 
go/no-go task, 63 participants for the dot probe task and 62 for the EMA assessment. The results 
of the QSU-brief indicate that craving levels were comparable in both treatment conditions in the 
morning but increased in the afternoon only in the placebo condition, whereas they decreased 
slightly in the NRT condition (see Table 1). 
 
3.2.2. Pharmacological intervention 
The mean use of placebo nasal spray was 1.41 times (SD=1.0) and of the active nasal 
spray 0.78 (SD=0.84). Several participants reported the sensation of the active nasal spray to be 
unpleasant. The patch generally seemed to be tolerated well. Participants guessed administration 
of active NRT correctly most of the time (80%), but were less accurate when guessing allocation 
of placebo (60%). 
 
3.2.3. Go/no-go task 
There was evidence for higher error rates in the placebo condition than in the active NRT 
condition (t[66 ] = 2.32, p = 0.024) (see Table 4.). Ad-hoc analysis revealed that there were no 
session – order effects for go/no-go task performance or ambulatory craving assessments. Go/no 
go commission error rates and ambulatory measures of craving were not associated (RC = 0.010, 
p = 0.192), and neither were go/no-go commission error rate and a craving x treatment 
interaction (RC = 0.002, p = 0.828). 
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3.2.4. N-back task 
There was no clear evidence of a difference between omission errors in the active NRT 
and placebo condition (t[66] = 0.42, p = 0.67) (see Table 4).  
 
3.2.5. Delay discounting task  
For the delay discounting task, there was no clear evidence of a difference between the 
logged values of the discounting parameter k in the active NRT and placebo conditions (t[68] = 
0.66, p = 0.51) (see Table 4). 
 
3.2.6. Dot probe task  
There was strong evidence of a main effect of dwell time on picture type (F[1, 62] = 
22.67, p < 0.0001), with more time spent looking at smoking over neutral pictures and of a main 
effect of session (F[1, 62] = 8.11, p = 0.006), with participants in the placebo condition spending 
more time looking at pictures regardless of type. There was no clear evidence of a picture × 
session interaction effect (F[1,62] = 0.73, p = 0.40). There was strong evidence of a main effect 
of picture type on direction of first saccade (F[1, 62] = 13.14, p < 0.001), but no clear evidence 
of a main effect of session (F[1, 62] = 0.05, p = 0.82), or of a picture × session interaction effect 
(F[1,62] = 1.10, p = 0.31) (for mean differences see Table 4). 
 
3.2.7. Ecological momentary assessment  
Each participant received about 4.3 prompts (SD 1.70) per session and the duration 
between first and last prompt was 3.52 hours (SD 1.51) on average The number of prompts 
received  did not differ greatly between conditions (N[placebo] = 269, N[active NRT] = 257). 
Compliance was good with 89 % of all prompts answered, more prompts were missed in the 
placebo than in the active condition (N[placebo] = 31, N[active] = 21). The mean craving score 
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in the placebo condition was 73.5 (SD 20.4) and in the NRT active condition 54.4 (SD 27.5). 
The mean craving score for the very first prompt received was 74.72 (SD 20.45) in the placebo 
condition and 50.88 (SD 8.85) in the active NRT condition. 
Treatment condition (active NRT versus placebo) was found to be highly predictive of 
craving levels (RC = -18.59, p < 0.0001) when included as the only predictor of craving in the 
model, with those in the NRT group reporting significantly lower levels of craving. Time was 
also found to weakly predict craving when added to the model (RC = 0.01, p = 0.013), by 
slightly increasing. There was weak evidence for an effect of the condition × time interaction 
term (RC = 0.02, p = 0.066). The decrease of the effect of treatment on craving in model 3 is 
likely due to multicollinearity, which inflated the standard error (see Table 5).  
 
3.3 Discussion 
Our go/no-go data indicated that commission error rate is sensitive to nicotine 
administration during smoking abstinence, while our EMA data indicated that ambulatory 
measures of cigarette craving are highly sensitive to nicotine administration during acute 
abstinence. There was no clear evidence that the N-back, delay discounting or dot probe task 
performance were sensitive to treatment.  
 
4. General Discussion 
The effects of changes to the abstinence state on cognitive task performance and craving 
in smokers were investigated in order to support the development of a human screening model of 
smoking abstinence. We found an increase in craving during acute abstinence in experiment 1 
and during placebo NRT administration in experiment 2. We furthermore found a decline in 
go/no-go task performance during acute abstinence in experiment 1 and during administration of 
placebo NRT in experiment 2, even though this effect was much smaller. Delay discounting, 
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working memory and attentional bias task performance were not found to be sensitive to either 
acute abstinence or nicotine administration.  
The increase of ambulatory ratings of cigarette craving during tobacco abstinence and 
decrease during NRT administration is in line with previous findings (Shiffman et al., 2006). 
This supports the assumption that craving levels assessed by EMA might be more sensitive to 
NRT in a short-term abstinence setting than when assessed using other methods (Teneggi et al., 
2002). However, contrary to our expectations we did not find a strong effect of time on craving 
levels in the abstinent condition in experiment 1 and in the placebo condition in experiment 2. 
One potential explanation for this is that craving levels might have reached a ceiling at the start 
of the EMA, due to the relatively late start in the day of the EMA assessment and the smoking 
cues used in the preceding task battery. This is supported by the observation that the first craving 
levels recorded were already close to mean craving levels in both the abstinent condition in 
experiment 1 and the placebo condition in experiment 2.  
The decrements found on the go/no-go task in abstinent smokers are likely a result of 
impaired response inhibition rather than general cognitive impairments, as we only found the 
hypothesized difference between conditions in commission error rates and no difference on other 
measures, such as reaction times or omission errors (Smith et al., 2014) in both experiments. Our 
finding that attentional bias, measured via eye-movements, was not affected by acute abstinence 
is consistent with previous findings showing that attentional bias measures for substance-related 
cues have poor internal reliability (Ataya et al., 2012). The fact that the effect of abstinence on 
go/no-go performance was relatively small and that none of the other cognitive measures, 
identified by a systematic review of the literature, were affected by acute abstinence aligns with 
conclusions from our previous work: research on acute abstinence and cognitive performance 
should give higher priority to statistical power and focus on the replication of results (Grabski et 
al., 2016). 
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Interestingly go/no-go performance and craving levels were not associated with each 
other. This could be due to the fact that they represent different abstinence phenotypes, but 
generally the two measures described should be compared with caution as there were 
considerable differences both in the number of assessments (single vs multiple time points) as 
well as the assessment methodology (lab-based vs experience sampling). 
The effect of abstinence was much more pronounced for measures of craving than for 
go/no-go performance in both experiments. Despite this we would argue for retaining both of 
these components in the model: Firstly, the difference in magnitude might partially be driven by 
the differences in assessment method discussed above.  Secondly, and more importantly, an 
objective validation of self-report measures is a crucial addition to a treatment screening model, 
especially given the difficulty of adequately blinding non-pharmacological as well as 
pharmacological treatments (Bello et al., 2016). Arguably an objective performance measure is 
not as likely to be influenced by participants correctly guessing treatment allocation as a 
subjective performance measure.  
Future studies might investigate ambulatory assessments of craving, and potentially other 
measures related to smoking withdrawal such as negative affect or stress, as well as go/no-go 
task performance, which will allow for a better comparisons between the two model 
components. Furthermore, well-controlled studies assessing the relationship between the model 
components and smoking cessation outcomes would increase the model’s ecological validity. 
This could inform on whether increasing go/no-go task performance to aid cessation, similar to 
efforts of decreasing craving, might be a worthwhile target for interventions as proposed 
previously (Ashare et al., 2014; Sofuoglu, DeVito, Waters, & Carroll, 2013). 
A particular strength of this series of experiments is the agnostic approach taken in the 
set-up of the cognitive task battery. The decision on which tasks to include was preliminarily 
based on findings from a previous systematic review, making the rationale comprehensible and 
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objective. Given the lack of a predominant theory predicting and explaining how specific 
cognitive domains might be affected during tobacco abstinence this was considered the ideal 
procedure to identify cognitive tasks reliably sensitive to changes in the withdrawal state. 
For both experiments the following limitations apply: First, the short-term design of both 
experiments does not allow conclusions about whether any of the changes observed actually 
relate to subsequent smoking cessation, which should be addressed in further research. For 
example, the current findings could be combined with a longer term experimental medicine 
model of abstinence, such as developed by Perkins and colleagues (Perkins et al., 2006). Second, 
the inclusion criterion of a minimum of five cigarettes smoked per day might have caused a 
sample with relatively low tobacco dependence, which could have influenced the results, as task 
performance decrements have been found to be exacerbated in heavier smokers (Sweitzer et al., 
2008). Third, the inclusion of less demanding versions of performance tasks, such as a 1-back 
version of the N-back, next to the 2-back version could have elucidated whether sensitivity to 
abstinence was associated with task difficulty. Fourth, screening for medication or recreational 
drug use was done via self-report only. Furthermore recent use of permitted drugs (eg. cannabis) 
was not recorded. Fifth, both studies were not double-blind. The first experiment did not allow 
for the blinding of neither participants nor the researcher, and in the second experiment only 
participants were blinded to the NRT condition. Furthermore, we were not able to tailor the 
nicotine dose according to the dose participants were accustomed to. Thus, for some participants 
the dose might have been either too high or too low, both of which could result in decrements of 
task performance, introducing uncontrolled error to the results. Related to the previous point, the 
exclusion of four participants (5% of those tested) due to adverse reactions to the active NRT 
might have introduced bias to our sample as smokers who are able to tolerate the treatment in 
combination with lengthy laboratory test sessions might also differ on other aspects from the 
general smoking population. Lastly, the current study design does not allow for an investigation 
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on whether changes in task performance were due to withdrawal or an ‘offset effect’ (Hughes, 
2007) (i.e., sustained changes following drug cessation, rather than the transient effects of 
withdrawal). Whether the effects of abstinence are transient is difficult to determine in a short-
term study. Nevertheless, whether the changes in go/no-go task performance and craving 
observed are a direct result of withdrawal or an offset effect should not affect the value of our 
findings as they could both drive relapse, and could therefore act as an indicator of treatment 
results. 
Novel smoking cessation treatments are an important way to improve population health. 
Our findings from two separate experimental studies converge to suggest that go/no go task 
performance as well as ambulatory cravings assessments are reliably sensitive to acute 
abstinence in smokers. Future studies should investigate whether these changes in the abstinent 
state are predictive of smoking cessation success. This model might then be utilized to 
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 M SD M SD 
CO (ppm)       
Morning 15.62 5.6 7.73 2.65 1.64 <0.0001 
Afternoon 14.35 6.02 5.27 2.89 1.75 <0.0001 
QSU-Brief       
Morning       
QSU Total 16.10 9.95 26.06 9.02 1.04 <0.0001 
QSU Factor 1 18.72 10.32 31.97 8.59 1.38 <0.0001 
QSU Factor 2 13.48 10.64 20.14 10.70 0.63 <0.0001 
Afternoon       
QSU Total 19.39 11.58 31.13 7.99 1.17 <0.0001 
QSU Factor 1 22.55 12.30 36.81 6.42 1.27 <0.0001 
QSU Factor 2 16.23 12.05 25.88 11.24 0.83 <0.0001 
 
Experiment 2 
      




 M SD M SD 
CO (ppm)       
Morning 6.66 2.57 5.75 2.98 0.22 0.063 
Afternoon 4.61 2.70 3.21 2.39 0.10 0.398 
NS use 1.41 1.00 0.78 0.84 - - 
M check 64 - 84 - - - 
QSU-Brief       
Morning       
QSU Total 26.95 7.65 26.33 7.38 0.10 0.388 
QSU Factor 1 20.17 8.50 19.34 7,73 0.13 0.286 
QSU Factor 2 33.74 8.46 33.31 8.49 0.06 0.636 
Afternoon       
QSU Total 22.85 5.70 28.69 7.08 0.89 <0.0001 
QSU Factor 1 14.92 4.83 22.14 8.18 0.92 <0.0001 
QSU Factor 2 30.78 8.09 35.25 0.76 0.62 <0.0001 
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Table 2. Test Battery Results (Experiment 1). 
 
 Satiated Abstinent Effect Size 
(d) 
95% CI p 
 M SD M SD 
Go/no-go        
CE 1.68 1.97 2.67 3.90 0.29 -1.89, -0.08 0.034 
OE 0.09 0.41 0.19 0.79 0.15 -0.26, 0.06 0.211 
RTs (sec) 0.83 0.06 0.83 0.08 0.09 -0.01, 0.02 0.471 




Log (k) 0.013 0.023 0.012 0.018 0.10 0.250 
N-Back        
CE 5.85 7.42 6.60 7.39 0.22 -0.49, 1.97 0.228 
OE 5.33 5.36 6.37 5.97 0.17 -0.42, 2.51 0.160 
RTs (sec) 1.31 0.69 1.30 0.64 0.02 -0.11, 1.10 0.868 
Dot Probe        
Dwell Time* 2.35 3.69 2.69 3.39 0.07 -0.87, 1.54 0.584 
Direction 1st Saccade* 5.67 8.50 6.97 8.48 0.12 -1.48, 4.07 0.353 
 
* m and sd values represent mean difference (smoking vs neutral pictures); p-values represent  interaction of picture 
x session;  CE: Commission errors, OE: Omission Errors.  
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Table 3. Results: Craving and Abstinence (EMA Experiment 1). 
 
 [1]   [2]   [3]   
 
RC SE p RC SE p RC SE p 
 
Condition -33.39 3.34 <0.0001 -33.21 2.15 <0.0001 -2.53 16.67 0.87 
Time    -0.02 0.01 0.16 0.04 0.03 0.19 
Condition-time       -0.04 0.02 0.06 
 
[1]: model including main variable “condition”, (no. observations: 584), [2]: model including main variables 
“condition” and “time”, (no. observations: 575), [3]: model including main variables “condition”, “time” and a 
“condition-time” interaction term (no. observations: 575), Condition: abstinence vs. satiation, Time=minutes since 
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Table 4. Test Battery Results (Experiment 2). 
 
 NRT Placebo 
Effect Size (d) 95% CI p 
 M SD M SD 
Go/No-Go        
CE 2.17 2.96 3.29 4.55 0.28 0.16, 2.08 0.024 
OE 0.02 0.17 0.02 0.17 0.00 -0.06, 0.06 1.000 
RTs (sec) 0.36 0.06 0.36 0.06 0.03 -0.01, 0.01 0.832 
Delay Discounting        




N-Back        
CE 6.74 9.31 5.21 8.05 0.20 -0.30, 3.37 0.100 
OE 5.85 4.54 6.10 5.76 0.05 -1.45, 0.94 0.673 
RTs (sec) 1.14 0.56 1.17 0.54 0.07 -0.14, 0.08 0.566 
Dot Probe        
Dwell Time* 1.41 2.27 0.92 3.50 0.11 -1.61, 0.64 0.396 
Direction 1st Saccade* 4.27 10.05 2.60 9.65 0.13 -4.90, 1.57 0.308 
 
* mean and sd represent mean difference (smoking vs neutral pictures); p-values represent  interaction of picture x 
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Table 5. Results Craving and Treatment (EMA Experiment 2). 
 
 [1]   [2]   [3]   
 
RC SE p RC SE p RC SE p 
 
Treatment -18.59 3.08 <0.001 -18.62 3.04 <0.001 -34.41 9.05 0.0001 
Time    0.01 0.01 0.013 -0.01 0.01 0.267 
Treatment-time       0.02 0.01 0.066 
 
[1]: model including main variable “treatment”, (no. observations: 515), [2]: model including main variables 
“treatment” and “time”, (no. observations: 515), [3]: model including main variables “treatment”, “time” and a 
“treatment-time” interaction term, (no. observations: 515), Treatment: placebo vs. NRT, Time: minutes since 
midnight. (placebo [1], active NRT [2]) 
 
 
 
